A Business at a Glance
0 of 1 daily views used (1 remaining). Sign up free for +5 more daily views (6 total), or try AAPL for a full preview.
PROVECTUS BIOPHARMACEUTICALS, INC.
PVCT
$30M
Mkt Cap
$0.06
+3.55%
PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT) has a 5-year average return on invested capital (ROIC) of -128.9%. This is below average and may indicate limited pricing power.
PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT) has a market capitalization of $27M. It is classified as a small-cap stock.
PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT) does not currently pay a regular dividend.
PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT) generated $-3 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT) reported earnings per share (EPS) of $-0.01 in its most recent fiscal year.
The Ledger Terminal provides 9 years of financial data for PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
ITEM 1. BUSINESS. Provectus Biopharmaceuticals, Inc., a Delaware corporation (together with its subsidiaries, “Provectus” or “the Company”), is a clinical-stage biotechnology company developing immunotherapy medicines for different diseases. Our drug product candidates are based on bioactive, synthetic, small molecule rose bengal sodium (“RBS”), which is a member of a class of molecules called halogenated xanthenes (“HXs”). The Company’s proprietary, patented, pharmaceutical-grade RBS is the active pharmaceutical ingredient (“API”) in all our clinical development and non-clinical research programs. The Company is the first entity to advance RBS into clinical trials for the treatment of disease. The Company is also the first entity, and currently the only one, to date to make pharmaceutical-grade RBS API consistently at a purity of nearly 100%. RBS can be delivered by different routes of administration.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2015 |
|---|---|---|---|---|---|---|
| Revenue | 350K | - | - | - | - | 0 |
| Net Income | -6.6M | -4.7M | -3.1M | -3.6M | -5.5M | -25M |
| EPS | $-0.01 | $-0.01 | $-0.01 | $-0.01 | $-0.01 | $-0.13 |
| Free Cash Flow | 0 | -3.3M | -2.6M | -3.0M | -1.0M | -17M |
| ROIC | -1224.6% | -355.8% | -158.2% | -132.9% | -105.1% | -119.4% |
| Gross Margin | - | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Debt/Equity | 0.00 | -0.03 | -0.11 | -0.10 | -0.30 | 0.25 |
| Dividends/Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | -6.5M | -4.5M | -2.9M | -3.4M | -4.7M | -25M |
| Operating Margin | -1857.3% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| ROE | 0.0% | - | - | - | - | -118.1% |
| Shares Outstanding | 420M | 473M | 310M | 355M | 554M | 188M |
| Metric | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | N/A | 0 | 0 | 0 | 0 | N/A | N/A | N/A | N/A | 350K |
| Gross Margin | N/A | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | N/A |
| R&D | 8.8M | 5.0M | 3.6M | 5.8M | 11M | 2.6M | 2.4M | 1.7M | 2.0M | 2.2M |
| SG&A | 12M | 8.7M | 8.8M | 11M | 13M | 2.1M | 2.0M | 1.7M | 3.2M | 4.7M |
| EBIT | -21M | -14M | -13M | -13M | -25M | -4.7M | -3.4M | -2.9M | -4.5M | -6.5M |
| Op. Margin | N/A | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | -1857.3% |
| Net Income | -20M | -13M | -29M | -10M | -25M | -5.5M | -3.6M | -3.1M | -4.7M | -6.6M |
| Net Margin | N/A | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | -1892.8% |
| Non-Recurring | 55K | 55K | 55K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Returns on Capital | ||||||||||
| ROIC | -169.0% | N/M | -51.4% | -48.2% | -119.4% | -105.1% | -132.9% | -158.2% | N/M | N/M |
| ROE | -190.0% | -176.9% | -524.2% | N/A | -118.1% | N/A | N/A | N/A | N/A | 0.0% |
| ROA | -141.8% | -130.4% | -220.4% | -44.3% | -105.1% | -270.1% | -128.1% | -178.0% | -385.5% | -1579.7% |
| Cash Flow | ||||||||||
| Op. Cash Flow | -17M | -11M | -86M | -14M | -17M | -1.0M | -3.0M | -2.6M | -3.3M | -3.4M |
| Free Cash Flow | -17M | -11M | -86M | -14M | -17M | -1.0M | -3.0M | -2.6M | -3.3M | 0 |
| Owner Earnings | -21M | -12M | -86M | -14M | -19M | -1.1M | -3.1M | -2.7M | -4.7M | -5.6M |
| CapEx | 6K | 16K | 7K | 71K | 6K | 0 | 0 | 0 | 0 | 0 |
| Maint. CapEx | 417K | 423K | 429K | 438K | 451K | 91K | 102K | 111K | 118K | 2K |
| Growth CapEx | 0 | 0 | 0 | 0 | 0 | N/A | N/A | N/A | N/A | 0 |
| D&A | 417K | 423K | 429K | 438K | 451K | 91K | 102K | 111K | 118K | 2K |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | ||||||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 48K | 48K | 48K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Stock-Based Comp | 3.4M | 183K | 142K | 116K | 671K | 24K | 3K | 3K | 1.3M | 2.2M |
| Debt Repayment | 2.4M | 2.4M | 2.4M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Balance Sheet | ||||||||||
| Net Debt | N/A | -722K | -15M | N/A | N/A | 577K | 603K | 723K | -101K | 1.1M |
| Cash & Equiv. | 7.7M | 1.2M | 16M | 17M | 14M | 683K | 22K | 77K | 307K | 145K |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 24K |
| Debt/Equity | 0.33 | 0.11 | 0.08 | N/A | 0.25 | -0.30 | -0.10 | -0.11 | -0.03 | 0.00 |
| Interest Coverage | -2.6 | N/A | N/A | N/A | N/A | -4.9 | -1005.6 | -513.5 | -333.5 | -333.5 |
| Equity | 10M | 4.4M | 6.6M | N/A | 16M | -4.2M | -6.2M | -7.6M | -6.0M | -6.2M |
| Total Assets | 13M | 6.2M | 20M | 26M | 20M | 3.5M | 2.0M | 1.4M | 1.0M | 420K |
| Total Liabilities | 3.3M | 1.8M | 13M | N/A | 4.1M | 7.7M | 8.3M | 9.0M | 7.0M | 6.6M |
| Intangibles | 7.8M | N/A | 5.9M | 5.0M | 4.0M | 227K | 338K | 425K | 539K | 539K |
| Retained Earnings | -106M | -118M | -146M | -156M | -181M | -246M | -250M | -253M | -257M | -262M |
| Working Capital | 7.4M | N/A | 15M | 18M | 11M | -4.3M | -6.3M | -7.7M | -6.0M | -6.2M |
| Current Assets | 7.7M | N/A | 16M | 19M | 15M | 3.4M | 1.9M | 1.4M | 977K | 278K |
| Current Liabilities | 263K | 511K | 513K | 848K | 4.1M | 7.7M | 8.2M | 9.0M | 7.0M | 6.5M |
| Per Share Data | ||||||||||
| EPS | -0.18 | -0.11 | -0.22 | -0.06 | -0.13 | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Owner EPS | -0.19 | -0.10 | -0.66 | -0.08 | -0.10 | -0.00 | -0.01 | -0.01 | -0.01 | -0.01 |
| Book Value | 0.09 | 0.04 | 0.05 | N/A | 0.09 | -0.01 | -0.02 | -0.02 | -0.01 | -0.01 |
| Cash Flow/Share | -0.16 | -0.10 | -0.65 | -0.08 | -0.09 | -0.00 | -0.01 | -0.01 | -0.01 | -0.02 |
| Dividends/Share | N/A | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Shares Out. | 110.6M | 115.9M | 131.3M | 170.7M | 188.5M | 554.0M | 355.5M | 310.2M | 473.3M | 420.3M |
| Valuation | ||||||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -6.4 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | 8.6 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Sales | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 77.0 |
| FCF Yield | -19.9% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Cap | 87M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 27M |
| Avg. Price | 0.94 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.06 |
| Year-End Price | 0.78 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.06 |
PROVECTUS BIOPHARMACEUTICALS, INC. passes 0 of 9 quality checks, indicating weak fundamentals.
PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT) has a book value per share of $-0.01, based on its most recent annual SEC filing.